Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R21) | Apply Online

FAQs: NIH RFA-DA-09-018 - Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R21)

What is the focus of NIH funding opportunity RFA-DA-09-018?

This funding opportunity supports exploratory research on how chronic pain changes the central nervous system (CNS) over time and how those pain-related CNS changes resemble, overlap with, or differ from CNS changes involved in drug addiction. It also emphasizes understanding how analgesic drugs affect these CNS adaptations, including when analgesics are used with pain versus in the absence of pain.

Which NIH Institutes are involved in this opportunity?

The opportunity is sponsored by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS).

What grant mechanism does this announcement use?

This announcement uses the NIH R21 mechanism, which is designed for exploratory and developmental projects. R21s are typically used for early-stage, higher-risk studies that test novel ideas or generate preliminary data that could support future, larger projects.

What kinds of scientific questions is the FOA trying to answer?

The FOA is centered on how chronic pain, analgesia, and drug addiction intersect in the CNS. It calls for studies that clarify shared versus distinct mechanisms and aims to improve understanding of how pain treatment might interact with addiction-related vulnerabilities.

What are the main research areas emphasized in this FOA?

The FOA emphasizes three connected lines of inquiry: (1) defining how chronic pain alters the CNS over time, including the temporal course of neurobiological adaptations; (2) studying how different classes of analgesic drugs influence pain-driven CNS alterations (for example, whether treatments reverse, worsen, or modulate those changes); and (3) examining CNS effects of analgesics used in the absence of pain, especially for drugs with abuse potential, to understand how drug exposure alone may contribute to addiction-related neural changes.

Does the FOA require comparative work across pain, analgesia, and addiction?

Yes. A central theme is comparative research that explicitly compares and contrasts CNS adaptations across chronic pain states, therapeutic analgesia, and drug abuse/addiction-related conditions. Applications are expected to go beyond describing changes in isolation and instead identify shared pathways and distinct signatures across these conditions.

What does the FOA mean by identifying shared versus distinct mechanisms?

The FOA is looking for studies that can separate mechanisms that overlap across chronic pain and addiction (such as shared circuitry, signaling systems, or synaptic plasticity mechanisms) from mechanisms that are unique to pain states, unique to addiction states, or specific to therapeutic versus abuse-related drug effects.

Are studies on timing and progression of CNS changes in chronic pain relevant?

Yes. The FOA specifically highlights interest in the temporal course of CNS changes in chronic pain, including how neurobiological adaptations emerge and evolve over time.

Are analgesic drug effects on the CNS part of the scope?

Yes. The FOA encourages research on how different classes of analgesic drugs influence pain-driven CNS adaptations, including whether particular treatments reverse, worsen, or otherwise modulate pain-associated CNS changes.

Does the FOA support research on analgesic exposure without pain?

Yes. The FOA explicitly highlights the importance of studying what happens when analgesics are used in the absence of pain, particularly for drugs with abuse potential, to understand how exposure alone can drive CNS changes related to reinforcement, dependence, addiction vulnerability, or long-term neural remodeling.

Does the FOA mention environmental or genetic factors?

Yes. The FOA notes interest in environmental and genetic factors that shape CNS changes. Examples of moderators mentioned include stress, context, learning history, and inherited biological differences that may influence susceptibility, resilience, or trajectories over time.

Are there companion funding opportunities with the same scientific scope?

Yes. This R21 is part of a coordinated set of announcements with identical scientific scope offered under other mechanisms: an R01 companion (RFA-DA-09-017) for more extensive projects and an R03 companion (RFA-DA-09-019) for smaller, short-term studies.

How should an applicant choose between the R21 and the companion R01 or R03?

Applicants were expected to select the mechanism that best fits the maturity and scale of their proposed work while still addressing the core scientific questions about CNS intersections among chronic pain, analgesia, and addiction. The R21 is positioned for exploratory, early-stage studies compared with the larger-scale R01 or the smaller, short-term R03.

How much funding was set aside and how many awards were anticipated?

NIDA set aside $2,000,000 and anticipated approximately 6 to 10 awards. NINDS set aside $375,000 and anticipated supporting about two grants across this FOA and its companion announcements (R01 and R03). The total estimated funding listed is $2,375,000.

When was this opportunity posted and what were the key dates?

The opportunity was posted on October 30, 2008. The original and current closing date was January 28, 2009. The archive date was February 28, 2009, indicating this was a time-limited solicitation.

Is this an open-ended program announcement or a time-limited solicitation?

It was a time-limited solicitation. The presence of a fixed closing date and an archive date indicates the FOA was not open-ended.

Who is eligible to apply under this FOA?

Eligibility was broad and included many organization types typically allowed under NIH research grants. Eligible applicants included public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and multiple levels of government (state and local, including counties, cities or townships, special districts). The FOA also included public housing authorities/Indian housing authorities, independent school districts, tribal entities (federally recognized tribal governments and other tribal organizations), U.S. territories or possessions, and non-U.S. entities (foreign organizations).

Does the FOA specifically encourage applications from certain institution types?

The eligibility language explicitly includes Alaska Native and Native Hawaiian Serving Institutions, Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and faith-based or community-based organizations, among others.

Are foreign organizations eligible?

Yes. The eligibility description explicitly includes non-U.S. entities (foreign organizations).

Is cost sharing or matching required?

No. The FOA states there is no cost sharing or matching requirement, consistent with standard NIH practice.

What is the intended impact or payoff of the research supported by this FOA?

The intended payoff is a clearer mechanistic foundation for developing pain treatments that provide relief while reducing risk for misuse or addiction, along with improved insight into the neurobiology linking persistent pain states and substance use disorders.